Oncology Pricing & Reimbursement

Summary

This event will present a fresh and original perspective on communicating the costeffectiveness of high value oncology drugs to key stakeholders. Unlike other general pricing & reimbursement meetings which are broadly focused, this event will focus on oncology therapy and will provide all participants with real-life case studies on how to increase market access and deliver cost value to the right stakeholders.

Speakers include:

Health Ministries and Health Insurance representatives

• Indiana Office of Medicaid Planning and Policy, USA - Director, Health

Quality, Policy Research and Strategic Planning

• NHS Innovations London - Head of Health Outcomes Unit
• SZP (Slovak common insurance) - Director
• Interamerican, Greece EUREKO Group - Health Director

Health Technology Assessors

• Gesundheit Österreich GmbH, Vienna - Pharmaceutical Policy Expert

Industry Experts

• Astellas, UK - Vice President, Medical Affairs & Health Economics Europe
• Sanofi-Aventis, France - Associate Director, Health Economics and Reimbursement, Oncology
• GlaxoSmithKline, UK - Director, Global Health Outcomes, Oncology
• Bayer AG, Hungary - Governmental Affairs Manager
• GlaxoSmithKline, Germany - Director Clinical Research

Leading Academics

• Swedish Institute for Health Economics (IHE) - CEO and Research Director,
• Institute for Economic Research, Lund University - Professor
• Tufts Center for the Study of Drug Development, USA - Assistant Director

Market Analysts and Consultants

• Global Insight, UK - Head of Research Unit
• Bridgehead International - Director of Pricing and Reimbursement
• Bridgehead International - Principal Consultant

Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

Why attend?
Benchmark, network and co-operate with policy makers and key influencing figures. Get

the best and most focused picture of oncology reimbursement models today. Get updated with their innovative agreement solutions and future trends. Learn how drug effectiveness is being demonstrated in different regions. Understand the best ways to communicate value and achieve maximum patient and market access.

Hear the perspectives off all stakeholder groups: Ministries of Health, HTA Agencies,
Insurers, doctors, health economics and the pharmaceutical industry. Discover how payers are taking pro-active reimbursement approach. Understand what patients want and what they view as quality treatment.